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Objectives: Compounds characterized by a peroxidic skeleton are an interesting starting point for antischisto-
somal drug discovery. Previously a series of 3-alkoxy-1,2-dioxolanes, which are chemically stable cyclic perox-
ides, demonstrated significant in vitro activity against Plasmodium falciparum. We aimed to evaluate the
potential of these compounds against Schistosoma mansoni and elucidate the roles of iron and peroxidic
groups in activity.
Methods: Drugs were tested against juvenile and adult stages of S. mansoni in vitro and in vivo. Selected struc-
tures were assessed in vitro against schistosomes in the presence of additional iron sources. In addition, drugs
were tested in vitro and in vivo against Echinostoma caproni, a non-blood-feeding intestinal fluke. Finally, the
activity of non-peroxidic analogues was evaluated.
Results: Three dioxolanes displayed IC50s ≤20.1 mM against adult schistosomes and values as low as 4.2 mM
against newly transformed schistosomula. Nonetheless, only moderate, non-significant worm burden reduc-
tions were observed after treatment of mice harbouring adult infections. Drugs lacked activity against juvenile
schistosomes in vivo. Two selected dioxolanes showed in vitro activity against E. caproni down to concentrations
of 5 mg/L, but none of the compounds revealed in vivo activity. All tested non-peroxidic analogues lacked ac-
tivity in vitro against both parasites.
Conclusions: Selected dioxolanes presented interesting in vitro activity, but low in vivo activities have to be over-
come to identify a lead candidate. Although the inactivity of non-peroxidic analogues underlines the necessity
of a peroxide functional group, incubation of adult schistosomes with additional iron sources did not alter ac-
tivity, supporting an iron-independent mode of activation.
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Introduction
Schistosomiasis is a neglected tropical disease caused by
trematode flatworms of the genus Schistosoma. Five species of
schistosomes infect humans, with Schistosoma haematobium,
Schistosoma japonicum and Schistosoma mansoni being respon-
sible for the main burden of schistosomiasis.1 Approximately
200 million people are affected by schistosomiasis, mainly in sub-
Saharan Africa.2 Praziquantel is currently the gold standard for the
treatment of schistosome infections. Because of the threat of drug
resistance and the limitations in the activity profile of praziquantel
(the drug lacks activity against the juvenile schistosome stages),
identification of potential drug candidates has a high priority.
The antischistosomal potential of the antimalarials artemisi-
nin and its semisynthetic derivatives artesunate and artemether
has been studied thoroughly in the past three decades, in in vitro
and in vivo studies, and in clinical trials.3–5 Given the promising
activity profile of the artemisinins, with particularly high activities
observed against juvenile schistosomes, different groups of fully
synthetic peroxides have been studied in vivo and in vitro in
recent years.6,7 For example, the synthetic trioxolane OZ418
was recently introduced as a promising drug candidate
showing high worm burden reductions (WBRs) of 80% and
86% against S. mansoni and S. haematobium, respectively.8
The high antimalarial activity of 1,2,4-trioxolanes triggered
investigations with 1,2-dioxolanes, which are structurally
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analogous five-membered ring peroxides offering enhanced
chemical stability. However, the dioxolanes proved much less
active than the corresponding 1,2,4-trioxolanes against Plasmo-
dium falciparum in vitro and Plasmodium berghei in vivo.9 This re-
duction in activity has been attributed to a decreased tendency
for scission of the alkoxy radicals derived from Fe(II) activation of
the 1,2-dioxolane peroxide;10 b-scission to generate carbon radi-
cals is considered important for the activity of peroxide antima-
larials.11 3-Alkoxy-1,2-dioxolanes, which undergo activation by
Fe(II) to generate oxygen-substituted alkoxy radicals closely
related to the intermediates derived from trioxolanes, generate
products indicative of efficient b-scission and have been shown
to have promising antimalarial efficacy.10
To our knowledge the antischistosomal activity of the
3-alkoxy-1,2-dioxolanes has not been studied to date. In the
present work 18 selected 3-alkoxy-1,2-dioxolanes were tested
on S. mansoni in vitro and active candidates were followed up
in vivo. To investigate whether the peroxide pharmacophore is
an essential requirement for antischistosomal activity, non-
peroxidic analogues of active compounds were synthesized
and their antischistosomal potential was determined. In add-
ition, the relationship between the parasite’s haemoglobin con-
sumption and the antischistosomal activity of compounds was
studied in vitro by testing active compounds on the
non-blood-feeding foodborne trematode Echinostoma caproni
and evaluating the in vitro activity of active compounds under
different incubation conditions, in media containing haemin,
haemoglobin or red blood cells.
Materials and methods
Drugs
The 18 3-alkoxy-1,2-dioxolane substrates illustrated in Table 1 were pre-
pared based upon methods described by Schiaffo et al.10 Two non-
peroxidic analogues were prepared as illustrated in Figure S1 (available
as Supplementary data at JAC Online).
Animals and parasites
Animal studies were conducted following Swiss regulations on animal
welfare at the Swiss Tropical and Public Health Institute (Basel, Switzer-
land, permission no. 2070). Three-week-old (weight 14 g) female
NMRI mice were purchased from Charles River (Sulzfeld, Germany) or
Harlan Laboratories (Horst, The Netherlands). Before starting experi-
ments, animals were allowed to adapt for 1 week under controlled con-
ditions (temperature 228C; humidity 50%; 12 h light and 12 h dark
cycle; free access to rodent diet and water). Infection of mice with
S. mansoni (Liberian strain) was performed subcutaneously by injection
Table 1. Chemical structures of investigated 3-alkoxy-1,2-dioxolanes and determined IC50 values (mean of three experiments) against newly
transformed schistosomula (NTS) and adult S. mansoni 72 h post-compound exposure; r represents goodness of fit (conformity with r≥0.85)
Compound
R2 R3
OR
O O
R1 IC50 (mM) for S. mansoni
R1 R2 R3 R NTS r adult r
1 Me Me Me 31.1 0.9 11.9 1.0
2 Me Bu Me CH2CH2Ph 7.5 1.0 12.4 1.0
3 -(CH2)5- CH2CH2Ph CH2CH2Ph 4.2 0.9 20.1 0.8
4 Me Me CH2Ph Me 101.0 0.7 49.2 1.0
5 O
O O
17.0 0.7 76.4 1.0
6 Me Me Me 5,6-epoxyhexyl 35.9 0.9 101.5 1.0
7 Me Me Me CH2CH2CN 89.2 1.0 137.0 1.0
8 -(CH2)5- Me CH(OH)CH2OH 90.9 0.9 138.4 1.0
9 Me Me Me (CH2)9CO2Me 89.7 0.9 169.3 0.9
10 Me Me Me CH2CH2CO2Me 76.0 1.0 206.2 1.0
11 Me Me Me CH2CH2OMe 69.2 0.8 207.4 0.9
12 Me Me Me CH2CH2 CH2OH 42.6 0.8 235.8 0.9
13 Me Me Me (CH2)4CO2Me 59.8 1.0 283.3 0.6
14 Me Me Me CH(OH)CH2OH 102.5 0.9 .436
15 Me Me Me CH2CH2Ph 2.7 0.9 58.4 0.9
16 -(CH2)5- Me CH2CH2Ph 2.8 0.9 49.4 0.9
17 -(CH2)5- Me
OH
4.1 0.9 71.8 1.0
18 Me Me Me
CO2Me
4.8 0.9 109.3 0.9
Praziquantel 2.2 0.9 0.08a
Artesunate 5.0 0.9 41.2 0.8
aAs described by Keiser et al.26
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of 80–100 cercariae. Cercariae were harvested from infected intermedi-
ate host snails (Biomphalaria glabrata) by exposure to light for 3 h, follow-
ing the standard procedures of our laboratory. For in vitro and in vivo
studies with E. caproni, mice were infected intragastrically with 30 meta-
cercariae harvested from infected B. glabrata snails.
In vitro screening
Preparation of NTS and adult schistosomes
NTS were obtained by mechanical transformation of S. mansoni cer-
cariae.12,13 Cercariae were collected as described above. The schistoso-
mula suspension was adjusted to a concentration of 100 NTS per
50 mL with Medium 199 (Invitrogen, Carlsbad, CA, USA) supplemented
with 5% heat-inactivated fetal calf serum (iFCS), 100 U/mL penicillin
and 100 mg/L streptomycin (Invitrogen). To ensure completed conversion
from cercariae to NTS, suspensions were incubated at 378C in an atmos-
phere of 5% CO2 in ambient air for a minimum of 12–24 h until use.
14
Adult flukes were harvested from hepatic portal veins and mesenteric
veins of infected NMRI mice (7–8 weeks post-infection) following stand-
ard procedures.6 Schistosomes were placed in RPMI 1640 culture
medium supplemented with 5% iFCS, 100 U/mL penicillin and 100 mg/L
streptomycin at 378C in an atmosphere of 5% CO2 until use.
Preparation of adult E. caproni
Infected mice were killed 2 weeks post-infection. Trematodes were har-
vested from the excised small intestine and placed in RPMI medium sup-
plemented with 100 U/mL penicillin, 100 mg/L streptomycin and 1%
a-D-glucose (Sigma Aldrich, St Louis, MO, USA). Flukes were maintained
at 378C in an atmosphere of 5% CO2 in ambient air until use.
Drug susceptibility assays with NTS
Drug dilution series with concentrations ranging from 0.37 to 90 mg/L
(0.37, 1.1, 3.3, 10, 30, 90 mg/L) were prepared in 96-well flat-bottom
plates (BD Falcon, USA) using supplemented medium (with iFCS and anti-
biotics). Prepared NTS suspension containing 100 NTS per 50 mL was
added to each well to yield a total volume of 250 mL per well. The
highest DMSO concentration (1.1%) used, diluted in Medium 199,
served as control. Plates were incubated at 378C in an atmosphere of
5% CO2. NTS were evaluated by microscopic readout (Carl Zeiss,
Germany, magnification ×80) with regard to death, changes in motility,
viability and morphological alterations 24, 48 and 72 h post-drug expos-
ure. As described previously, drug effects were evaluated using a viability
scale.12,13 Parasite fitness, morphology and motility were classified with
scores ranging from 3 (normal activity, no morphological changes) to 0
(all worms dead). Duplicate examinations were performed for each con-
centration and experiments were repeated at least three times. IC50
values of the investigated drugs based on motility scale values obtained
at the 72 h timepoint were determined using CompuSyn software
(Version 3.0.1, 2007; ComboSyn, Inc.).
Drug susceptibility assay with adult schistosomes
In vitro screening on adult flukes was performed in 24-well flat-bottom
plates (BD Falcon, USA). Supplemented RPMI 1640 medium (with iFCS
and antibiotics) and drug stock solutions (10 mg/mL) were used to
obtain final test concentrations of 1–90 mg/mL (1.1, 3.3, 10, 30, 90 mg/L)
in wells with a final volume of 1.4 mL. Finally, three schistosomes of
both sexes were added to each well. The highest concentration of
DMSO (0.3%) in medium served as control. Twenty-four, 48 and 72 h
post-drug exposure, phenotypes were monitored using the motility
scale described by Ramirez et al.15 and an inverse microscope (Carl
Zeiss, Germany, magnification ×80). Experiments were performed three
times. IC50 values were calculated with CompuSyn software as described
above for NTS (Version 3.0.1, 2007; ComboSyn, Inc.).
Drug susceptibility assay of adult S. mansoni in the
presence of haemin, haemoglobin or red blood cells
Lead candidates were incubated as described above, but using different
RPMI culture medium conditions. A haemin solution (1.5 mM) was pre-
pared as follows: 50 mg haemin chloride (Fluka Analytical, The Nether-
lands) was dissolved in 10 mL of 0.1 M NaOH, 0.5 mL of 1 M HCl and
39.5 mL of PBS (pH¼7.4). The haemoglobin solution (0.23 mM) was pre-
pared using 750 mg haemoglobin from bovine blood (Sigma Aldrich, USA)
dissolved in the same amounts of NaOH, HCl and PBS as used above.
Finally, supplemented RPMI media were prepared by adding 8%
haemin solution, 10% haemoglobin solution or 2% red blood cells from
red blood cell concentrate (blood group A Rhesus positive) to final con-
centrations in well plates of 120 mM for haemin, 23 mM for haemoglobin
or 2% for red blood cells. At timepoints 24, 48 and 72 h post-exposure,
phenotypes were monitored using the motility scale as described
above using an inverse microscope (Carl Zeiss, Germany, magnification
×80) and data were compared between various incubation conditions.15
Isothermal microcalorimetry (IMC) drug assay with adult
S. mansoni
Two non-peroxidic analogues (compounds 19, 20) and one selected diox-
olane (compound 16) were further characterized using IMC as described
by Manneck et al.16 Briefly, heat production and motility (derived from
noise amplitudes) of schistosomes were measured using a 48-channel
microcalorimeter (model TAM 48; TA Instruments, New Castle, DE, USA)
over a period of 5 days. Samples were prepared in glass ampoules with
2900 mL of medium (supplemented RPMI 1640) containing four adult
worms. Pre-warmed (378C) ampoules were placed in channels and equili-
bration was performed for 12 h until a stable signal was observed. Drug
suspensions (concentration of 900 mg/L) in supplemented medium
(volume 100 mL) were injected, using 1 mL syringes (BD Plastipak,
Becton Dickinson S.A., Madrid, Spain), to reach the final concentration
of 30 mg/L per ampoule. Ampoules with dead worms served as the
negative control and ampoules with worms treated with the highest
concentration of DMSO (0.3%) served as the positive control. Heat flow
was recorded as 1 data point per 1 min over at least 120 h. Tests at
each concentration were performed three times.
Drug susceptibility assay with adult E. caproni
Assays were prepared in 24-well flat-bottom plates (Costar). Drug dilu-
tions were prepared with drug stock solutions and supplemented RPMI
medium (with antibiotics and glucose) to obtain final drug concentra-
tions of 5–100 mg/L (5, 10, 50, 100 mg/L) in a total volume of 2 mL
per well. Six to nine trematodes were used (one or two worms per
well) for each experimental group. The highest concentration of DMSO
(1%) served as control. Plates were incubated at 378C in an atmosphere
of 5% CO2. Twenty-four, 48 and 72 h post-drug exposure, phenotypes
and mortality of worms were monitored as described elsewhere.12
In vivo screening
Studies with S. mansoni
Groups of four infected NMRI mice characterized by a patent schistosome
infection (49 days post-infection) or a juvenile Schistosoma infection
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(21 days post-infection) were treated orally with the test drug using
single oral doses of 400 mg compound per kg body weight. Seven to
nine untreated mice served as controls. Animals harbouring an adult
Schistosoma infection were killed by the CO2 method 14 days post-
treatment, and mice treated at the juvenile infection stage were sacri-
ficed 4 weeks post-treatment. Mice were then dissected and worms
sexed and counted.6 Worm burdens of treated mice were compared
with those of untreated animals and reductions of worm burden
calculated.
Studies with E. caproni
Four NMRI mice were treated intragastrically with 400 mg/kg of test com-
pounds 2 weeks post-infection with E. caproni. Four mice were left un-
treated and served as controls. One week post-treatment, mice were
euthanized with CO2. At necropsy, the intestines were removed from
the pylorus to the ileocaecal valve, placed in a Petri dish and opened
longitudinally. All E. caproni worms were removed and counted.
Statistics
Parasite motility of treated and untreated NTS and adult trematodes
was calculated as mean (+SD) using Microsoft Excel software. Motility
data obtained from experiments with various media containing iron
sources were compared using the Mann–Whitney test (considered sig-
nificant at P≤0.05). IC50 values were determined using the CompuSyn
software (Version 3.0.1, 2007; ComboSyn, Inc.). For the comparison of
IC50 values we used the Kruskal–Wallis test (considered significant at
P≤0.05). The Kruskal–Wallis test was also used for in vivo studies,
comparing the medians of the responses between the treatment
and control groups. A difference in median was considered to be
significant at a significance level of 5% (StatsDirect statistical soft-
ware, version 2.7.2.; StatsDirect Ltd, UK). Noise amplitudes and heat
flows observed in calorimetric in vitro assays with adult S. mansoni
were analysed using R software and Microsoft Excel. As described by
Manneck et al.,17 noise amplitude values follow an exponential
decay. Endpoints of worm motility were determined by the intersec-
tion of the sample amplitude curve with the background signal
noise of dead worms.
Results
In vitro screening against S. mansoni
In a first step, 14 3-alkoxy-1,2-dioxolanes were studied against
adult S. mansoni in vitro. Three of the compounds (1, 2 and 3)
demonstrated good antischistosomal activity with IC50s of
11.9, 12.4 and 20.1 mM, respectively, against adult flukes. The
remaining 11 substances revealed only minor activity (IC50s
between 49.2 and 283.3 mM) or lacked activity (compound 14).
Good activities were observed against the juvenile schistosome
stage (NTS) for compounds 2 (IC50 7.5 mM) and 3 (IC50 4.2 mM).
Moderate activity was detected for compounds 1 (IC50
31.1 mM), 5 (IC50 17.0 mM) and 6 (IC50 35.9 mM) against NTS.
Finally, only minor activity was recorded for the remaining nine
compounds against NTS (IC50 42.6–102.5 mM). In vitro findings
are summarized in Table 1. For comparison, activities of standard
antischistosomal drugs, praziquantel and artesunate, are also
shown in Table 1.
Influence of haemin, haemoglobin or red blood cells on in
vitro antischistosomal activity
Incubation of adult schistosomes with various concentrations
(1.1, 3.3, 10, 30 mg/L) of the three active alkoxydioxolanes
(1–3) in supplemented media containing haemin, haemoglobin
or red blood cells showed no significant differences in activity.
The motilities recorded 72 h post-exposure of S. mansoni with
compound 1 at different concentrations did not vary among
the different media tested (Figure 1). Slightly higher, though
not significant (P.0.05) activities were detected for com-
pounds 2 and 3 when incubated in the presence of haemin
or haemoglobin. In the presence of these media all worms
had died 72 h post-exposure to the tested compounds at a
concentration of 10 mg/L and 30 mg/L.
In vivo activity of selected alkoxydioxolanes against
S. mansoni
The three lead structures 1–3 identified by prior in vitro screening,
were tested in a juvenile as well as an adult S. mansoni infection
mouse model (Table 2). All studied alkoxydioxolanes lacked in vivo
activity against juvenile S. mansoni (Table 2; WBRs 0%–4%).
However, moderate, non-significant activities were observed
with compounds 1 and 2 against adult S. mansoni with WBRs of
42.5% and 37.0%, respectively. Compound 3 showed only low ac-
tivity against adult S. mansoni in vivo with a WBR of 15.1%. Dead
worms were detected in mouse livers after treatment of adult
infections with compounds 1, 2 and 3. The presence of a patent
schistosoma infection in treated animals was confirmed by ob-
serving granulous tissue and Schistosoma eggs within all livers.
In vitro and in vivo activity of modified lead dioxolanes
against S. mansoni
Given the low in vivo activity of the three test drugs, we were
motivated to investigate four additional chemically related alkoxy-
dioxolanes in vitro against NTS and adult schistosomes, followed
by in vivo studies on a patent S. mansoni infection. All four com-
pounds (15–18) showed very high activities against NTS, repre-
sented by low IC50 values (2.7–4.8 mM) (summarized in
Table 1). However, the four drugs revealed only low activities
against adult schistosomes in vitro, with IC50s between 49.4
and 109.3 mM. Moderate, but non-significant, in vivo WBRs of
32.0% and 21.3% were achieved with compounds 15 and 17, re-
spectively. Low activities with WBRs of 12.0% and 16.4% were
observed with compounds 16 and 18, respectively (summarized
in Table 3).
In vitro and in vivo effect against E. caproni
Lead structures 1–3 as well as the four related structures
(15–18) were tested in vitro on freshly harvested E. caproni.
Data are summarized in Table 4. Six of seven compounds (1, 3,
15–18) showed 100% worm mortality 24 h post-drug exposure
at a concentration of 50 mg/L. Two of the compounds (16 and
17) killed all worms 24 h post-incubation at a 5-fold lower con-
centration of 10 mg/L. Incubation of adult E. caproni with three
spirocyclohexyl compounds (3, 16 and 17) at 5 mg/L for 72 h
resulted in death of all worms. Compounds 15–17 were followed
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up in vivo. Treatment of E. caproni-infected mice with a single
oral dose of 400 mg/kg of compound 15 resulted in a low WBR
of 17.4%. Compounds 16 and 17 lacked in vivo activity (Table 5).
In vitro activity of non-peroxidic analogues
To elucidate the role and necessity of the peroxide core of the
alkoxydioxolanes for trematocidal activity we tested the in vitro
activity of two alkoxy-substituted tetrahydrofurans (19, 20) pre-
pared as non-peroxidic analogues of the alkoxydioxolanes. Both
derivatives lacked activity at concentrations of 30 and 90 mg/L
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Figure 1. Motility of adult schistosomes 72 h post-treatment with various concentrations (1.1, 3.3, 10 and 30 mg/L) of compounds 1, 2 or 3 in four
different incubation settings. (a) Standard incubation with supplemented RPMI. (b) Addition of 2% red blood cells from red blood cell concentrate. (c)
Addition of 120 mM haemin. (d) Addition of 23 mM haemoglobin.
Table 2. In vivo activity following a single oral dose of 400 mg/kg of
selected 3-alkoxy-1,2-dioxolanes in mice harbouring juvenile or adult
S. mansoni
Group
No. of mice
investigated
No. of
mice that
died
No. of
mice
cured
TWR
(%)
P
value
FWBR
(%)
P
value
Control 8 0 0 2 2 2 2
Juvenile
infection
1 4 0 0 0 0.73 0 0.86
2 4 0 0 4.1 0.67 5.9 0.38
3 4 0 0 0 0.87 0 0.44
Adult
infection
1 4 0 0 42.5 0.27 47.1 0.23
2 4 0 0 37.0 0.35 41.2 0.35
3 4 0 0 15.1 0.86 17.7 0.73
TWR, total worm burden reduction; FWBR, female worm burden
reduction.
Table 3. In vivo activity following a single oral dose of 400 mg/kg of
selected 3-alkoxy-1,2-dioxolanes in mice harbouring adult S. mansoni
Group
No. of mice
investigated
No. of mice
that died
No. of
mice
cured
TWR
(%)
P
value
FWBR
(%)
P
value
Controla 7 0 0 2 2 2 2
Controlb 9 0 0 2 2 2 2
15a 4 1 0 32.0 0.1 37.8 0.1
16a 4 1 0 12.0 0.7 5.4 0.7
17a 4 1 0 21.3 0.4 35.1 0.3
18b 4 0 0 16.4 0.9 11.9 0.7
TWR, total worm burden reduction; FWBR, female worm burden
reduction.
aVersus control.
bVersus control.
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against S. mansoni. Also, E. caproni was not affected at 50 and
100 mg/L. No effect against adult S. mansoni could be observed
by microscopic examination 72 h post-treatment as well as by
IMC 6 days after treatment. According to IMC, no loss of motility
was detected for either non-peroxidic compound over an incuba-
tion period of 6 days (concentration 30 mg/L). For comparison,
treatment of adult S. mansoni with 30 mg/L of the peroxidic ana-
logue of compound 19 (compound 16) revealed a reduction
in heat flow and complete loss of motility was detected 90 h
post-exposure (Figure 2).
Discussion
The antischistosomal activity of semisynthetic artemisinins, fre-
quently used in malaria treatment, synthetic trioxolanes and
hybrid molecules of quinines and trioxanes has been well
described.7,8 Compounds characterized by a peroxidic skeleton
are therefore an interesting starting point for antischistosomal
drug discovery. Hence, we were interested in elucidating the anti-
schistosomal potential of recently introduced alkoxydioxolanes
as well as their structural needs for activity against
schistosomes.10
Three of 14 compounds tested (compounds 1–3) showed
promising in vitro activity against adult S. mansoni flukes. Two
of these compounds (2 and 3) also revealed very good efficacy
against the juvenile stage (NTS) in vitro. The antischistosomal
in vitro activity seems to be enhanced by the presence of a
bulky substituent at C3, since the three lead compounds all
feature a large alkoxide side chain at C3. The remaining non-
active 11 compounds do not display this feature. This finding is
in accordance with observations reported by Schiaffo et al.10
on the antimalarial structure–activity relationship of similar
compounds. These studies revealed that antimalarial activity is
enhanced by a spirocyclohexyl group at C5/C5′ and by the pres-
ence of a steric bulk at C3. However, for antischistosomal activity
it does not seem to matter whether substitution at C5/C5′ is a
dimethyl (compound 2) or spirocyclohexyl (compound 3) group.
On the other hand, it is interesting to note that, with regard to
E. caproni, the three most active compounds (3, 16 and 17) all
display spirocyclohexyl units.
In our in vivo studies we observed only moderate, non-
significant activities of alkoxydioxolanes in S. mansoni-infected
NMRI mice. Compound 1 showed the highest in vivo activity
against adult S. mansoni, achieving a total WBR of 42.5% and
a female WBR of 47.1%. In contrast to results reported for arte-
misinins, surprisingly low WBRs were observed against juvenile
S. mansoni harboured in mice.18 A recent study conducted with
a library of dioxolanes revealed that the majority of the com-
pounds tested against rat and human microsomes were meta-
bolized rapidly. It was concluded that significant optimization
of the groups attached to the dioxolane core is needed before
a viable candidate for drug development could be identified.19
Hence, it is likely that the alkoxydioxolanes tested in this study
also exhibit bioavailability problems which can likely play a role
in limiting in vivo activities.
In the present work we also studied the activity of alkoxydiox-
olanes in the presence of various additional iron sources, since
haemoglobin metabolism, the potential target of these drugs,
is a common feature of both Schistosoma and Plasmodium
Table 4. In vitro mortality of E. caproni worms at timepoints 24, 48 and
72 h post-drug treatment with selected compounds
Drug
Drug concentration
(mg/L)
No. of worms
observed
Percentage of worms
that died after indicated
time
0 h 24 h 48 h 72 h
Control 2 20 0 0 0 0
1 100 8 0 100
50 8 0 100
10 7 0 43 100
5 8 0 25 75 88
2 100 6 0 100
50 6 0 0 100
10 6 0 17 67 100
5 7 0 0 29 57
3 100 6 0 100
50 7 0 100
10 7 0 57 100
5 9 0 22 100
15 100 6 0 100
50 6 0 100
10 7 0 86 100
5 8 0 0 38 75
16 100 6 0 100
50 6 0 100
10 7 0 100
5 6 0 50 67 100
17 100 6 0 100
50 7 0 100
10 6 0 100
5 7 0 0 100
18 100 6 0 100
50 7 0 100
10 6 0 67 83 100
5 6 0 0 17 33
Table 5. In vivo activity following a single oral dose of 400 mg/kg of
selected 3-alkoxy-1,2-dioxolanes against E. caproni in mice
Group
No. of mice
investigated
No. of mice
cured Worms
TWR
(%)
P
value
Control 4 0 23.0 (0) 2 2
15 4 0 19.0 (7.2) 17.4 0.2
16 4 0 27.8 (4.5) 0 0.2
17 4 0 23.0 (7.8) 0 0.5
TWR, total worm burden reduction.
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spp.20 Earlier studies investigated the relationship between Fe(II)
reactivity, the efficiency of haem alkylation and antimalarial ac-
tivity for various peroxides in vitro. The authors stated that Fe(II)
reactivity for the tested peroxide heterocycles is a necessary, but
insufficient, property of antimalarial peroxides,21 and the alkoxy-
dioxolanes have been shown to undergo cleavage to alkoxy radi-
cals in the presence of iron(II).10 Interestingly, we did not
observe significant differences in susceptibility of the tested
agents in the different iron-source-containing media. This
finding is in contrast to the haemin-dependent antischistosomal
in vitro effect of the trioxolane OZ78 on S. mansoni and S. japo-
nicum, whereas similar haemin-independent activity was
described for OZ209.6,22 Similarly, it was recently shown that
the antimalarial arylmethanol mefloquine, a drug class also
described to interfere with haemoglobin degradation in Plasmo-
dium, revealed a 57-fold lower IC50 in the presence of haemoglo-
bin against adult S. mansoni in vitro.23 Our results suggest that
the alkoxydioxolanes possess an iron-independent mechanism
of action on schistosomes in vitro. This discovery is supported
by the observed high in vitro activities of three compounds (3,
16 and 17) at concentrations as low as 5 mg/L against the non-
haematophagous intestinal fluke E. caproni.
Nonetheless, the results with the isosteric compounds that
lack a peroxide functional group underline the necessity of
the peroxidic core for trematocidal activity. Both compounds
lacked in vitro activity against adult S. mansoni and E. caproni.
Similar results were recently demonstrated in studies with the
liver fluke Fasciola hepatica. While OZ78 has excellent in vitro
and in vivo activity against F. hepatica, its non-peroxidic ana-
logue failed to show an effect against the fluke.24 The peroxidic
feature seems therefore to play a role in the iron-independent
mode of action. The basis for the iron-independent activity
of the alkoxydioxolanes is unclear. These molecules, like all
peroxides, are oxidants, and in principle capable of reaction
with strongly nucleophilic or reducing agents. Alternatively, it
is possible that the alkoxydioxolanes undergo activation via
acid-catalysed ring opening of the peroxyacetal core to gener-
ate a more reactive 3-hydroperoxyketone; a similar model has
been proposed to account for the antimalarial activity of
artemisinin.25
In conclusion, we have demonstrated that a number of alkoxy-
dioxolanes are characterized by good in vitro antischistosomal ac-
tivity and non-significant in vivo effects on S. mansoni, with
compound 1 being the most promising candidate. Similarities,
but also differences, exist between antimalarial and antischistoso-
mal activity of alkoxydioxolanes. The peroxidic bond is essential to
antischistosomal activity, but activation of the molecules seems
to be independent of iron. The low in vivo activity of this drug
class, which may result from limited bioavailability, represents a
challenge that would need to be overcome in order to identify
an antischistosomal lead candidate.
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